What to use in future for active #Sjogren's #SjD B cell depletion, signal attenuation Ianalumab 2+ phase3 RCTs Telitacept +RCT Nipocalimab FcRn +Ph2 Dazodalibep CD40L +Ph2 +RCTs HCQ+Lef Rituximab ?BTKi #ACR25 @ACRheum @RheumNow abst#LB24, LB11

#MTX is NOT the same as TCZ in #GCA in RCT #TCZ did better So use an advanced Rx for GCA ex TCZ, Upa when approved METOGiA RCT - more relapses in MTX abst#891 #ACR25 @ACRheum @RheumNow https://t.co/wsEKGF8dW2

• https://x.com/Janetbirdope/status/1983654734646108174/photo/1

When should you order a renal bx in suspected #LN? Active urinary sediment Used to be #UPCR 500g/g or more Abst#772 looked at UPCR 250g/g to 499 71% + LN and half needed Rx esp if Low C3,C4 Black race Petri, Baltimore #lupus #cohort #ACR25 @ACRheum @RheumNow

#Ianalumab decreases disease activity in active #Sjögren's #disease 2 phase3 DB #RCT added to #SoC in primary #SjD >90% #Ro+ +#ESSDAI in monthly sc dosing vs placebo, Many 2ndary outcomes improved, safe LB#24 #ACR25 @ACRheum @RheumNow #ACRBest https://t.co/Z4ooUg7Nos

• https://x.com/Janetbirdope/status/1983603226328076798/photo/1
• https://x.com/Janetbirdope/status/1983603226328076798/photo/1

TAC+MMF + GC vs TAC +GC in lupus nephritis (target trial emulation): 🔹Higher total renal response w/ TAC + MMF + GC at 12 mo (59.7% vs 33.3%) consistent in ITT & per-protocol 🔹similar adverse events reported (14.6% vs 16.4%) @RheumNow #ACR25 https://t.co/Yuql3O9C8X

• https://x.com/AkhilSoodMD/status/1983590907095011839/photo/1

#ACR25 Abstr#2695 Inguinal lymph node biopsies pre- and post-OBI, RTX, BLIN & CD19 CAR-T showed complete tissue depletion with CAR-T. B-cells reduced but often incomplete with protein-based depleters; OBI being the best. Still don’t agree with “immune reset” @RheumNow #ACRBest https://t.co/Sq7m9sXlLP

• https://x.com/Yuz6Yusof/status/1983587064802316679/photo/1
• https://x.com/Yuz6Yusof/status/1983587064802316679/photo/1

#2682 In a randomised trial of 320 RA patients, the recombinant zoster vaccine (RZV) was safe and did not trigger disease flares. But methotrexate use and older age significantly blunted antibody responses ➡️key factors to consider for vaccine strategies in RA. @RheumNow #ACR25

kids w 👇 Undifferentiated #systemic #autoinflammatory #disease Rx #IL1i N=33 =boys &girls 3.5 yrs Sx Abst#2151 #ACR25 @ACRheum @RheumNow There are many periodic fever syndromes 🤔some mutations are not yet discovered Access to &use of Anakinra canukinumab Rilonacept https://t.co/IyTx0nFxKC

• https://x.com/Janetbirdope/status/1983584894690189449/photo/1

#2659 In a large real-world target trial (>1.3M with T2D), SGLT2 inhibitors, esp dapagliflozin & empagliflozin, were assoc with lower risks of RA, lupus, vasculitis & other autoimmune rheumatic diseases vs DPP-4 inhibitors. Possible immune benefits of SGLT2i? @RheumNow #ACR25

Abstract 2697: Compared to MMF, tacrolimus showed - similar SRR by week 96 (58.5% vs. 69.2%, OR 0.62; 95% CI 0.29-1.29) - similar time to renal AE/deaths (HR 0.70; 95% CI 0.37-1.35) - serious AEs less frequent (12.3% vs. 30.8%) @RheumNow #ACR25 https://t.co/o3LtgOp7St

• https://x.com/AkhilSoodMD/status/1983581595979117052/photo/1

#ACR25 Abstr#2697 H2H RCT of Tacrolimus + GC vs MMF + GC in #lupus Nephritis in Asia for Induction-Maintenance showed similar efficacy. Different side effects: AKI more in TAC, low WCC & infections in MMF. Informative for services with no access to biologics/Voclosporin @RheumNow https://t.co/V4uWhuqjjW

• https://x.com/Yuz6Yusof/status/1983578834315157825/photo/1

#2658 In >870k adults with T2DM or obesity, GLP-1 receptor agonists showed no increase in autoimmune or inflammatory disease risk, and were instead linked to lower mortality, heart failure, stroke and dementia. Excellent real-world safety signals. @RheumNow #ACR25

Abstract 2695: Deep dive into B-cell depletion (BCD) Lymph node biopsy pre/post tx: 🔹 CAR T: complete BCD + disrupted follicular architecture 🔹 RTX, OBI, BLIN: reduced BCD + preserved follicular architecture ✅ Complete LN depletion → drug-free remission @RheumNow #ACR25

Year in Preview SLE: 52% subtherapeutic on weight based HCQ dosing Precision prescribing needed, more so for CKD @RheumNow #ACR25 Abstract 1722 https://t.co/8WqorQ1xJx

• https://x.com/JihaRheum/status/1983555467344310342/photo/1